URGN
UroGen Pharma Ltd. [URGN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
URGN Stock Summary
Top 10 Correlated ETFs
URGN
Top 10 Correlated Stocks
URGN
In the News
URGN Financial details
Company Rating
Sell
Market Cap
515.24M
Income
-102.24M
Revenue
82.71M
Book val./share
-1.8
Cash/share
3.81
Dividend
-
Dividend %
-
Employees
198
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-4.52
Forward P/E
-
PEG
2.04
P/S
5.82
P/B
-11.24
P/C
3.72
P/FCF
-5.28
Quick Ratio
6.21
Current Ratio
7.06
Debt / Equity
-1.52
LT Debt / Equity
-1.51
-
-
EPS (TTM)
-3.73
EPS next Y
-
EPS next Q
-
EPS this Y
-25.89%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-6.24%
Revenue last 5Y
440.08%
Revenue Q/Q
12.84%
EPS Q/Q
5.88%
-
-
-
-
SMA20
-6.67%
SMA50
-12.5%
SMA100
16.67%
Inst Own
57.18%
Inst Trans
1.01%
ROA
-54%
ROE
108%
ROC
-0.42%
Gross Margin
88%
Oper. Margin
-92%
Profit Margin
-135%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
8.69-24.13
52W High
-40.92%
52W Low
+77.25%
RSI
46
Rel Volume
0.62
Avg Volume
354.62K
Volume
218.75K
Perf Week
9.5%
Perf Month
-21.35%
Perf Quarter
26.83%
Perf Half Y
8.49%
-
-
-
-
Beta
1.084
-
-
Volatility
0.59%, 1.32%
Prev Close
-0.42%
Price
14.18
Change
-2.94%
URGN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0.54 | 2.15 | 2.82 | 2.87 | |
| Net income per share | -4.9 | -5.9 | -4.96 | -4.79 | -3.55 | |
| Operating cash flow per share | -3.46 | -4.86 | -3.8 | -3.84 | -2.65 | |
| Free cash flow per share | -3.48 | -4.92 | -3.83 | -3.85 | -2.66 | |
| Cash per share | 7.16 | 7.03 | 3.99 | 4.38 | 4.78 | |
| Book value per share | 8.78 | 4.42 | 0.38 | -3.89 | -2.26 | |
| Tangible book value per share | 8.78 | 4.42 | 0.38 | -3.89 | -2.26 | |
| Share holders equity per share | 8.78 | 4.42 | 0.38 | -3.89 | -2.26 | |
| Interest debt per share | -0.08 | 0.17 | 0.95 | 4.76 | 4.7 | |
| Market cap | 685.04M | 392.49M | 212.52M | 202.3M | 432.51M | |
| Enterprise value | 637.96M | 290.08M | 168.56M | 246.01M | 436.91M | |
| P/E ratio | -6.81 | -3.05 | -1.92 | -1.85 | -4.23 | |
| Price to sales ratio | 38.06K | 33.26 | 4.42 | 3.14 | 5.23 | |
| POCF ratio | -9.65 | -3.71 | -2.5 | -2.31 | -5.66 | |
| PFCF ratio | -9.6 | -3.66 | -2.48 | -2.3 | -5.65 | |
| P/B Ratio | 3.8 | 4.07 | 25.26 | -2.28 | -6.63 | |
| PTB ratio | 3.8 | 4.07 | 25.26 | -2.28 | -6.63 | |
| EV to sales | 35.44K | 24.58 | 3.51 | 3.82 | 5.28 | |
| Enterprise value over EBITDA | -5.9 | -2.29 | -2.25 | -3.15 | -6.84 | |
| EV to operating cash flow | -8.98 | -2.74 | -1.99 | -2.81 | -5.72 | |
| EV to free cash flow | -8.94 | -2.71 | -1.97 | -2.8 | -5.71 | |
| Earnings yield | -0.15 | -0.33 | -0.52 | -0.54 | -0.24 | |
| Free cash flow yield | -0.1 | -0.27 | -0.4 | -0.43 | -0.18 | |
| Debt to equity | 0.01 | 0.03 | 0.44 | -1.13 | -1.52 | |
| Debt to assets | 0.01 | 0.03 | 0.03 | 0.73 | 0.56 | |
| Net debt to EBITDA | 0.44 | 0.81 | 0.59 | -0.56 | -0.07 | |
| Current ratio | 7.63 | 5.39 | 5.11 | 5.39 | 5.42 | |
| Interest coverage | 25.27 | -355.01 | -5.29 | -9.37 | -1.81 | |
| Income quality | 0.68 | 0.82 | 0.77 | 0.8 | 0.75 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 3.34K | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 2.74K | 4.01 | 0.99 | 0.82 | 0.55 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0.01 | 0.01 | 0 | 0 | |
| Capex to revenue | -18.06 | -0.1 | -0.02 | 0 | 0 | |
| Capex to depreciation | -0.25 | -0.59 | -0.42 | -0.14 | -0.11 | |
| Stock based compensation to revenue | 1.66K | 2.38 | 0.48 | 0.16 | 0.11 | |
| Graham number | 31.11 | 24.23 | 6.48 | 20.47 | 13.43 | |
| ROIC | -0.56 | -1.29 | -7.46 | -6.19 | -1.95 | |
| Return on tangible assets | -0.5 | -1.05 | -0.93 | -0.8 | -0.57 | |
| Graham Net | 6.09 | 6.14 | -0.49 | -4.97 | -3.17 | |
| Working capital | 129.15M | 94.18M | 92.01M | 104.99M | 137.97M | |
| Tangible asset value | 180.3M | 96.36M | 8.41M | -88.74M | -65.21M | |
| Net current asset value | 126.55M | 89.97M | 3.06M | -96.07M | -74.34M | |
| Invested capital | 0.01 | 0.03 | 0.44 | -1.13 | -1.52 | |
| Average receivables | 0 | 3.52M | 9.38M | 12.21M | 14.07M | |
| Average payables | 6.62M | 3.98M | 4.53M | 5.66M | 6.02M | |
| Average inventory | 0 | 982K | 3.4M | 4.58M | 5M | |
| Days sales outstanding | 0 | 218 | 89.02 | 72.05 | 68.15 | |
| Days payables outstanding | 0 | 1.18K | 409.52 | 263.57 | 253.99 | |
| Days of inventory on hand | 0 | 710.47 | 342 | 206.25 | 221.2 | |
| Receivables turnover | 0 | 1.67 | 4.1 | 5.07 | 5.36 | |
| Payables turnover | 0 | 0.31 | 0.89 | 1.38 | 1.44 | |
| Inventory turnover | 0 | 0.51 | 1.07 | 1.77 | 1.65 | |
| ROE | -0.56 | -1.33 | -13.17 | 1.23 | 1.57 | |
| Capex per share | -0.02 | -0.06 | -0.03 | -0.01 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.78 | 0.74 | 0.9 | 0.65 | 0.65 | |
| Net income per share | -1.22 | -1.3 | -1.03 | -0.68 | -0.72 | |
| Operating cash flow per share | -0.94 | -1.11 | -0.86 | -0.54 | -0.36 | |
| Free cash flow per share | -0.94 | -1.11 | -0.86 | -0.54 | -0.36 | |
| Cash per share | 4.33 | 2.79 | 2.02 | 4.56 | 3.81 | |
| Book value per share | -3.84 | -5.01 | -5.9 | -1.3 | -1.8 | |
| Tangible book value per share | -3.84 | -5.01 | -5.9 | -1.3 | -1.8 | |
| Share holders equity per share | -3.84 | -5.01 | -5.9 | -1.3 | -1.8 | |
| Interest debt per share | 4.47 | 4.46 | 4.44 | 3.23 | 3 | |
| Market cap | 204.8M | 215.11M | 242.83M | 452.5M | 542.3M | |
| Enterprise value | 248.51M | 277.91M | 322.21M | 432.74M | 546.7M | |
| P/E ratio | -1.81 | -1.78 | -2.52 | -5.17 | -5.21 | |
| Price to sales ratio | 11.32 | 12.51 | 11.49 | 21.7 | 23.05 | |
| POCF ratio | -9.42 | -8.34 | -11.98 | -26.16 | -41.54 | |
| PFCF ratio | -9.41 | -8.33 | -11.97 | -26.01 | -41.37 | |
| P/B Ratio | -2.31 | -1.85 | -1.75 | -10.78 | -8.32 | |
| PTB ratio | -2.31 | -1.85 | -1.75 | -10.78 | -8.32 | |
| EV to sales | 13.74 | 16.17 | 15.24 | 20.75 | 23.23 | |
| Enterprise value over EBITDA | -12.5 | -13.25 | -22.15 | -35.53 | -38.54 | |
| EV to operating cash flow | -11.42 | -10.77 | -15.89 | -25.02 | -41.87 | |
| EV to free cash flow | -11.42 | -10.76 | -15.88 | -24.87 | -41.7 | |
| Earnings yield | -0.14 | -0.14 | -0.1 | -0.05 | -0.05 | |
| Free cash flow yield | -0.11 | -0.12 | -0.08 | -0.04 | -0.02 | |
| Debt to equity | -1.13 | -0.86 | -0.73 | -2.39 | -1.52 | |
| Debt to assets | 0.73 | 0.89 | 1.05 | 0.52 | 0.56 | |
| Net debt to EBITDA | -2.2 | -2.99 | -5.46 | 1.62 | -0.31 | |
| Current ratio | 5.39 | 3.8 | 3.04 | 7.06 | 5.42 | |
| Interest coverage | -6.29 | -6.2 | -4.09 | -3.54 | -1.61 | |
| Income quality | 0.75 | 0.85 | 0.84 | 0.79 | 0.5 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.8 | 0.73 | 0.55 | 0.49 | 0.48 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0.01 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.03 | -0.05 | -0.03 | -0.24 | -0.13 | |
| Stock based compensation to revenue | 0.13 | 0.13 | 0.11 | 0.11 | 0.11 | |
| Graham number | 10.29 | 12.09 | 11.69 | 4.45 | 5.4 | |
| ROIC | -1.57 | 1.49 | 0.42 | -0.23 | -0.49 | |
| Return on tangible assets | -0.21 | -0.27 | -0.25 | -0.11 | -0.15 | |
| Graham Net | -4.91 | -6.54 | -7.35 | -2.36 | -2.53 | |
| Working capital | 104.99M | 70.74M | 54.57M | 156.34M | 137.97M | |
| Tangible asset value | -88.74M | -116.55M | -138.43M | -41.99M | -65.21M | |
| Net current asset value | -96.07M | -133.54M | -152.46M | -53.5M | -74.34M | |
| Invested capital | -1.13 | -0.86 | -0.73 | -2.39 | -1.52 | |
| Average receivables | 11.07M | 12.6M | 14M | 14.18M | 14.15M | |
| Average payables | 4.04M | 6.25M | 5.81M | 4.35M | 5.28M | |
| Average inventory | 4.59M | 4.9M | 5.23M | 5M | 5.34M | |
| Days sales outstanding | 63.2 | 65.4 | 66.01 | 55.45 | 59.07 | |
| Days payables outstanding | 219.81 | 276.87 | 171.64 | 153.65 | 256.46 | |
| Days of inventory on hand | 172.01 | 217.19 | 183.76 | 190.19 | 223.35 | |
| Receivables turnover | 1.42 | 1.38 | 1.36 | 1.62 | 1.52 | |
| Payables turnover | 0.41 | 0.33 | 0.52 | 0.59 | 0.35 | |
| Inventory turnover | 0.52 | 0.41 | 0.49 | 0.47 | 0.4 | |
| ROE | 0.32 | 0.26 | 0.17 | 0.52 | 0.4 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
URGN Frequently Asked Questions
What is UroGen Pharma Ltd. stock symbol ?
UroGen Pharma Ltd. is a US stock , located in Princeton of Nj and trading under the symbol URGN
What is UroGen Pharma Ltd. stock quote today ?
UroGen Pharma Ltd. stock price is $14.18 today.
Is UroGen Pharma Ltd. stock public?
Yes, UroGen Pharma Ltd. is a publicly traded company.
Company Profile
- Volume Average 354.62K
- Market Capitalization 515.24M
- Employee 198
- CEO Ms. Elizabeth A. Barrett
- Headquarters Princeton,NJ,US
- IPO Date 2017-05-04
-
Website
https://www.urogen.com 
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
